TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.0510nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.0810nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.150nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.190nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.210nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.230nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.240nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.240nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.340nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.350nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.360nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.370nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.510nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.830nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.850nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.850nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 0.970nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 1.10nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 1.30nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 1.60nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 1.60nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 1.80nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 3.30nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 5.10nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 7.10nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 7.80nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 8.60nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataKi: 1.00E+3nMAssay Description:Inhibition of TYK2 JH1 domain (unknown origin) measured in presence of 10 uM ATPMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 17.7nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1× kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 17.7nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1x kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 24.2nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1x kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 24.2nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1× kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 33nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1x kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 33nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1× kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 47nMAssay Description:Inhibition of TYK2 in human PBMC assessed as inhibition of IL-12-stimulated phosphorylation of STAT4 measured by immunoblotting methodMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 56.9nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1× kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 56.9nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1x kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
Affinity DataIC50: 64nMAssay Description:Inhibition of Jak1/Jak3 in human PBMC assessed as inhibition of IL2-stimulated phosphorylation of STAT5More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 72.6nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1x kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 72.6nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1× kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 74.1nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1x kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 74.1nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1× kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 78.5nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1× kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 78.5nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1x kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 82nMAssay Description:Inhibition of TYK2 in human PBMC assessed as inhibition of IL-12-stimulated phosphorylation of STAT4 measured by immunoblotting methodMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 83nMAssay Description:Inhibition of TYK2 in human PBMC assessed as inhibition of IL-12-stimulated phosphorylation of STAT4 measured by immunoblotting methodMore data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 85.3nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1x kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 85.3nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1× kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 88.6nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1x kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Nimbus Therapeutics
Curated by ChEMBL
Nimbus Therapeutics
Curated by ChEMBL
Affinity DataIC50: 88.6nMAssay Description:Compounds were serially diluted in DMSO then further diluted in 1× kinase buffer: 5 uL of buffer diluted compound was added into wells first, then 10...More data for this Ligand-Target Pair